Integrated lung ultrasound score for early clinical decision-making in patients with COVID-19: results and implications.
COVID-19
Emergency Department
Integrated Lung Ultrasound Score (i-LUS)
Lung Ultrasound Score (LUS)
SARS-CoV-2
Journal
The ultrasound journal
ISSN: 2524-8987
Titre abrégé: Ultrasound J
Pays: Italy
ID NLM: 101742146
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
received:
14
09
2021
accepted:
29
03
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
Lung Ultrasound Score (LUS) identifies and monitors pneumonia by assigning increasing scores. However, it does not include parameters, such as inferior vena cava (IVC) diameter and index of collapse, diaphragmatic excursions and search for pleural and pericardial effusions. Therefore, we propose a new improved scoring system, termed "integrated" lung ultrasound score (i-LUS) which incorporates previously mentioned parameters that can help in prediction of disease severity and survival, choice of oxygenation mode/ventilation and assignment to subsequent areas of care in patients with COVID-19 pneumonia. Upon admission at the sub-intensive section of the emergency medical department (SEMD), 143 consecutively examined COVID-19 patients underwent i-LUS together with all other routine analysis. A database for anamnestic information, laboratory data, gas analysis and i-LUS parameters was created and analyzed. Of 143 enrolled patients, 59.4% were male (mean age 71 years) and 40.6% female. (mean age 79 years: p = 0.005). Patients that survived at 1 month had i-LUS score of 16, which was lower than that of non-survivors (median 20; p = 0.005). Survivors had a higher PaO2/FiO2 (median 321.5) compared to non-survivors (median 229, p < 0.001). There was a correlation between i-LUS and PaO2/FiO2 ratio (rho:-0.4452; p < 0.001), PaO2/FiO2 and survival status (rho:-0.3452; p < 0.001), as well as i-LUS score and disease outcome (rho:0.24; p = 0.005). In non-survivors, the serum values of different significant COVID indicators were severely expressed. The i-LUS score was higher (median 20) in patients who required non-invasive ventilation (NIV) than in those treated only by oxygen therapy (median 15.42; p = 0.003). The odds ratio for death outcome was 1.08 (confidence interval 1.02-1.15) for each point increased. At 1-month follow-up, 65 patients (45.5%) died and 78 (54.5%) survived. Patients admitted to the high critical ward had higher i-LUS score than those admitted to the low critical one (p < 0.003). i-LUS could be used as a helpful clinical tool for early decision-making in patients with COVID-19 pneumonia.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Lung Ultrasound Score (LUS) identifies and monitors pneumonia by assigning increasing scores. However, it does not include parameters, such as inferior vena cava (IVC) diameter and index of collapse, diaphragmatic excursions and search for pleural and pericardial effusions. Therefore, we propose a new improved scoring system, termed "integrated" lung ultrasound score (i-LUS) which incorporates previously mentioned parameters that can help in prediction of disease severity and survival, choice of oxygenation mode/ventilation and assignment to subsequent areas of care in patients with COVID-19 pneumonia.
METHODS
METHODS
Upon admission at the sub-intensive section of the emergency medical department (SEMD), 143 consecutively examined COVID-19 patients underwent i-LUS together with all other routine analysis. A database for anamnestic information, laboratory data, gas analysis and i-LUS parameters was created and analyzed.
RESULTS
RESULTS
Of 143 enrolled patients, 59.4% were male (mean age 71 years) and 40.6% female. (mean age 79 years: p = 0.005). Patients that survived at 1 month had i-LUS score of 16, which was lower than that of non-survivors (median 20; p = 0.005). Survivors had a higher PaO2/FiO2 (median 321.5) compared to non-survivors (median 229, p < 0.001). There was a correlation between i-LUS and PaO2/FiO2 ratio (rho:-0.4452; p < 0.001), PaO2/FiO2 and survival status (rho:-0.3452; p < 0.001), as well as i-LUS score and disease outcome (rho:0.24; p = 0.005). In non-survivors, the serum values of different significant COVID indicators were severely expressed. The i-LUS score was higher (median 20) in patients who required non-invasive ventilation (NIV) than in those treated only by oxygen therapy (median 15.42; p = 0.003). The odds ratio for death outcome was 1.08 (confidence interval 1.02-1.15) for each point increased. At 1-month follow-up, 65 patients (45.5%) died and 78 (54.5%) survived. Patients admitted to the high critical ward had higher i-LUS score than those admitted to the low critical one (p < 0.003).
CONCLUSIONS
CONCLUSIONS
i-LUS could be used as a helpful clinical tool for early decision-making in patients with COVID-19 pneumonia.
Identifiants
pubmed: 35648278
doi: 10.1186/s13089-022-00264-8
pii: 10.1186/s13089-022-00264-8
pmc: PMC9156837
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Informations de copyright
© 2022. The Author(s).
Références
Crit Care. 2019 Aug 28;23(1):288
pubmed: 31455421
Am J Respir Crit Care Med. 2004 Feb 1;169(3):336-41
pubmed: 14739134
Intensive Care Med. 2013 May;39(5):801-10
pubmed: 23344830
Intensive Care Med. 2020 Jul;46(7):1445-1448
pubmed: 32367169
N Engl J Med. 2008 Mar 27;358(13):1327-35
pubmed: 18367735
Ann Emerg Med. 2001 Oct;38(4):377-82
pubmed: 11574793
Intensive Care Med. 2021 Apr;47(4):444-454
pubmed: 33743018
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Insights Imaging. 2021 Jun 19;12(1):81
pubmed: 34146161
Intensive Care Med. 2020 Oct;46(10):1873-1883
pubmed: 32860069
Intensive Care Med. 2020 Sep;46(9):1707-1713
pubmed: 32728966
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Intensive Care Med. 2019 Sep;45(9):1200-1211
pubmed: 31418060
Chest. 2021 Jan;159(1):205-211
pubmed: 32835709
Respir Physiol Neurobiol. 2021 Feb;284:103585
pubmed: 33197604
J Ultrasound Med. 2020 Nov;39(11):2281-2282
pubmed: 32383793
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Anesthesiology. 2015 Feb;122(2):437-47
pubmed: 25501898
Chest. 2014 Dec;146(6):1586-1593
pubmed: 25144893
Echocardiography. 2020 Apr;37(4):625-627
pubmed: 32239532
Clin Chest Med. 2006 Jun;27(2):215-27
pubmed: 16716814
Intern Emerg Med. 2016 Apr;11(3):477-80
pubmed: 26746413
Crit Care. 2020 Dec 24;24(1):702
pubmed: 33357240
Intensive Care Med. 2020 May;46(5):849-850
pubmed: 32166346
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur Respir Rev. 2020 Apr 29;29(156):
pubmed: 32350086
Intensive Care Med. 2017 Jan;43(1):29-38
pubmed: 27620292
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Cardiovasc Ultrasound. 2012 Dec 04;10(1):49
pubmed: 23210515
Minerva Anestesiol. 2012 Nov;78(11):1282-96
pubmed: 22858877
Ultrasound J. 2020 Apr 21;12(1):22
pubmed: 32318891
Intensive Care Med Exp. 2019 Jul 25;7(Suppl 1):48
pubmed: 31346802
Acad Radiol. 2021 Sep;28(9):1323-1324
pubmed: 34275738
J Emerg Med. 2020 Sep;59(3):403-408
pubmed: 32712031
J Cardiothorac Vasc Anesth. 2021 Jun;35(6):1866-1874
pubmed: 32624431
Crit Care. 2016 Sep 28;20(1):305
pubmed: 27677861